Genzyme Corp. (NASDAQ:GENZ) announced Tuesday that itsdiagnostic products division has acquired Virotech System-Diagnostika GmbH for approximately $10 million.
Virotech, located in Russelsheim, Germany, develops,manufactures and markets ELISA test kits to diagnose avariety of infectious diseases. The principal sellers of privatelyheld Virotech were the Neu-Europa, IDP and VC BdW Germanventure capital groups.
"Virotech represents a key component of our long-termstrategy to develop and strengthen our diagnostic business inEurope," said David Fleming, president of Genzyme Diagnosticsof Cambridge, Mass.
(c) 1997 American Health Consultants. All rights reserved.